drugset / Trial / NCT01414920
Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the efficacy and safety of TAK-875, once daily (QD), in combination with sitagliptin QD in participants with type 2 diabetes mellitus (T2DM).
Timeline
- Start
- 2011-08
- Primary completion
- 2012-08
- Completion
- 2012-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fasiglifam | Small molecule | 25 mg | Oral |
| Subject | Fasiglifam | Small molecule | 50 mg | Oral |
| Subject | Sitagliptin | Small molecule | 100 mg | Oral |